1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 15 DECEMBER 2014

Cancer Drug News 15 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - Success Of Biotech Firms With CAR-T Candidates Drawing In Multinationals
Industry Brief - IBCSG/BIG/Merck Open Global Phase Ib/II Study In HER2+ BC
Industry Trend Analysis - Oncothyreon/Array Licensing Deal Opens Avenues For Both Firms
Industry Brief - Ignyta Receives Approval Of Nonproprietary Name Entrectinib For RXDX-101
Industry Brief - Nordic Nanovector Secures Japanese Patent Covering Radioimmunotherapy Technology
Industry Brief - BioLineRx Reveals Multi-Year Development Plan For BL-8040
Industry Brief - Teva Launches Erlotinib In Canada
Industry Brief - Xtandi Now Licensed In UK For Chemotherapy-Naïve MCRPCA
Industry Brief - Bavarian Nordic Reaches Enrolment Target In Prostvac Phase III PCA Study
Industry Brief - First Patient Dosed In Onapristone Phase II Study In APR Positive Endometrioid Tumours
Industry Brief - Insys' Liposome Entrapped Paclitaxel Receives FDA ODD For GC
Industry Trend Analysis - Cobimetinib/Zelboraf Combination Set To Take Melanoma Market Share
Industry Brief - OncoSec Initiates ImmunoPulse SCCHN Phase II Trial
Industry Trend Analysis - Pfizer Will Become Serious Contender In Immuno-Oncology
Industry Trend Analysis - Cancer - 2014 Industry Trends
Industry Brief - RedHill Submits Bekinda MAA For Oncology Support
Industry Brief - MEI To Raise Funds In Public Share Offering
Industry Brief - NetScientific Invests In PDS Biotechnology

Table Of Contents

Cancer Drug News 15 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Protein Kinase Inhibitors in Oncology: Analytical Tool

Protein Kinase Inhibitors in Oncology: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Conjugated Drugs in Oncology: Analytical Tool

Conjugated Drugs in Oncology: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Orphan Drugs in Oncology: Analytical Tool

Orphan Drugs in Oncology: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.